|
Bertram Brenig1, Julia Beck2, Ekkehard Schütz2, Howard B Urnovitz2 1University of Goettingen, Germany; 2Chronix Biomedical GmbH, Germany |
Abstract
Next generation sequencing technology provides significant promise in providing personalized medicine in the 21st century. A recent report has clearly demonstrated in a small number of patients that unique chromosomal rearrangements identified by next generation DNA sequencing can be detected in blood by PCR. Nevertheless significant barriers to successful translation of this advancement to clinical medicine exist that include knowledge of unique mutational lesions for each neoplasm and their fate during clonal expansion. We have used an alternative approach that is dependent on next generation sequencing of serum DNA and DNA motif identification and assembly (Mass Sequencing and Assembly or MSA) technology that requires no prior knowledge of specific mutational events in diseased tissue. We have successfully applied MSA technology to invasive breast carcinoma and neurodegenerative diseases of animals and humans. We believe this alternative approach provides an opportunity for translation of complex basic research data to personalized medicine.
| Back to NGS: Next Generation Sequencing |
|---|
